Entropy Technologies LP Invests $338,000 in ADMA Biologics Inc $ADMA

Key Points

• Entropy Technologies LP acquired a new stake in ADMA Biologics, purchasing 17,021 shares valued at approximately $338,000 during the first quarter.
• Insider transactions included significant sales, with Director Lawrence P. Guiheen selling 20,000 shares and Director Steve Elms selling 194,749 shares, reflecting substantial decreases in their holdings.
• ADMA Biologics reported earnings of $0.15 per share, surpassing analyst expectations, alongside a 13.8% year-over-year revenue increase to $121.98 million.

Entropy Technologies LP acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 17,021 shares of the biotechnology company's stock, valued at approximately $338,000.

Several other institutional investors also recently bought and sold shares of the company. Invesco Ltd. increased its holdings in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after purchasing an additional 1,570,649 shares during the period. Townsquare Capital LLC purchased a new position in ADMA Biologics during the 1st quarter worth $546,000. Citigroup Inc. increased its holdings in ADMA Biologics by 6.3% during the 1st quarter. Citigroup Inc. now owns 1,001,852 shares of the biotechnology company's stock worth $19,877,000 after purchasing an additional 59,669 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in ADMA Biologics by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,462,005 shares of the biotechnology company's stock worth $48,846,000 after purchasing an additional 21,711 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in ADMA Biologics by 24.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 23,325 shares of the biotechnology company's stock worth $463,000 after purchasing an additional 4,553 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 1.2%

Shares of ADMA Biologics stock traded down $0.2150 during trading on Tuesday, reaching $17.4150. The company's stock had a trading volume of 533,244 shares, compared to its average volume of 3,136,015. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 20.30 and a beta of 0.38. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company has a 50-day simple moving average of $18.22 and a two-hundred day simple moving average of $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. During the same quarter in the previous year, the firm posted $0.13 EPS. The firm's revenue was up 13.8% compared to the same quarter last year. As a group, equities analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insiders Place Their Bets

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director directly owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,621 shares of company stock valued at $9,644,269. 3.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ADMA shares. Raymond James Financial lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to data from MarketBeat, ADMA Biologics currently has an average rating of "Buy" and a consensus target price of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.